Evidence Table MULTI.3. DISCRETE Outcomes of MULTI-ARM Trials.

Trial	Discrete Outcome Name (Units) Comments re Between P-value	Follow up	Treatment	Between P-value
97 ↑ P Mild/mod	**Overall change/investigator**	Short (4)	**Benzoyl peroxide** improved 31 Same 14 worse 3	
97 ↑ P Mild/mod	**Overall change/investigator**	Short (4)	**Benzoyl peroxide + chlorhydroxyquinoline** improved 35 Same 11 worse 2	
97 ↑ P Mild/mod	**Overall change/investigator**	Short (4)	**Vehicle** improved 16 Same 18 worse 15	
119 ↑ P s	**Discontinuation due to side effects**	Short (3)	**Adapalene** discontinued 0	
119 ↑ P s	**Discontinuation due to side effects**	Short (3)	**Petrolatum** discontinued 1	
119 ↑ P s	**Discontinuation due to side effects**	Short (3)	**Tretinoin (0.01% gel)** discontinued 16	
119 ↑ P s	**Discontinuation due to side effects**	Short (3)	**Tretinoin (0.025% cream)** discontinued 5	
119 ↑ P s	**Discontinuation due to side effects**	Short (3)	**Tretinoin (0.025% gel)** discontinued 18	
119 ↑ P s	**Discontinuation due to side effects**	Short (3)	**Tretinoin (0.05% cream)** discontinued 13	
119 ↑ P s	**Discontinuation due to side effects**	Short (3)	**Tretinoin (0.1% cream)** discontinued 25	
120 ↑ P s	**Discontinuation due to side effects**	Short (3)	**Adapalene** discontinued 0	
120 ↑ P s	**Discontinuation due to side effects**	Short (3)	**Petrolatum** discontinued 0	
120 ↑ P s	**Discontinuation due to side effects**	Short (3)	**Tretinoin (0 .1% cream)** discontinued 7	
120 ↑ P s	**Discontinuation due to side effects**	Short (3)	**Tretinoin (0.025% cream)** discontinued 0	
120 ↑ P s	**Discontinuation due to side effects**	Short (3)	**Tretinoin (0.05% cream)** discontinued 3	
120 ↑ P s	**Discontinuation due to side effects**	Short (3)	**Tretinoin (0.1% gel)** discontinued 2	
132 ↑ P Sev	**Overall change**	Mid (12)	**Placebo** worse 1 No change 4 better 1	

↑↓ refer to the presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. BETWEEN P-value indicates a comparison among arms of the study.

Trial	Discrete Outcome Name (Units) Comments re Between P-value	Follow up	Treatment	Between P-value
132 ↑ P Sev	**Overall change**	Mid (12)	**Spironolactone (100)** worse 0 No change 3 better 2	
132 ↑ P Sev	**Overall change**	Mid (12)	**Spironolactone (150)** worse 0 No change 2 better 4	
132 ↑ P Sev	**Overall change**	Mid (12)	**Spironolactone (200)** worse 0 No change 1 better 3	
132 ↑ P Sev	**Overall change**	Mid (12)	**Spironolactone (50)** worse 0 No change 4 better 1	
132 ↑ P Sev	**Overall change/patient**	Mid (12)	**Placebo** worse 1 No change 4 better 1	
132 ↑ P Sev	**Overall change/patient**	Mid (12)	**Spironolactone (100)** worse 0 No change 1 better 4	
132 ↑ P Sev	**Overall change/patient**	Mid (12)	**Spironolactone (150)** worse 0 No change 1 better 5	
132 ↑ P Sev	**Overall change/patient**	Mid (12)	**Spironolactone (200)** worse 0 No change 0 better 4	
132 ↑ P Sev	**Overall change/patient**	Mid (12)	**Spironolactone (50)** worse 1 No change 2 better 2	
132 ↑ P Sev	**Overall change/photo**	Mid (12)	**Placebo** worse 3 No change 2 better 1	
132 ↑ P Sev	**Overall change/photo**	Mid (12)	**Spironolactone (100)** worse 1 No change 1 better 3	
132 ↑ P Sev	**Overall change/photo**	Mid (12)	**Spironolactone (150)** worse 0 No change 1 better 5	

↑↓ refer to the presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. BETWEEN P-value indicates a comparison among arms of the study.

Trial	Discrete Outcome Name (Units) Comments re Between P-value	Follow up	Treatment	Between P-value
132 ↑ P Sev	**Overall change/photo**	Mid (12)	**Spironolactone (200)** worse 1 No change 0 better 3	
132 ↑ P Sev	**Overall change/photo**	Mid (12)	**Spironolactone (50)** worse 1 No change 1 better 3	
149 ↓ P Mild/mod/sev	**Inflammatory changes (Witkowski discretized %)**	Mid (10)	**Benzoyl peroxide (10%)** Excellent (>75%) 18 Good (>50%) 10 Moderate + Poor (>0%) 3	**NS**
149 ↓ P Mild/mod/sev	**Inflammatory changes (Witkowski discretized %)**	Mid (10)	**Benzoyl peroxide (5%)** Excellent (>75%) 20 Good (>50%) 14 Moderate + Poor (>0%) 6	**NS**
149 ↓ P Mild/mod/sev	**Inflammatory changes (Witkowski discretized %)**	Mid (10)	**Tretinoin** Excellent (>75%) 23 Good (>50%) 4 Moderate + Poor (>0%) 4	**NS**
149 ↓ P Mild/mod/sev	**Non-inflammatory change (Witkowski discretized %)**	Mid (10)	**Benzoyl peroxide (10%)** Excellent (>75%) 25 Good (>50%) 8 Moderate + Poor (>0%) 1	
149 ↓ P Mild/mod/sev	**Non-inflammatory change (Witkowski discretized %)**	Mid (10)	**Benzoyl peroxide (5%)** Excellent (>75%) 27 Good (>50%) 10 Moderate + Poor (>0%) 4	
149 ↓ P Mild/mod/sev	**Non-inflammatory change (Witkowski discretized %)**	Mid (10)	**Tretinoin** Excellent (>75%) 32 Good (>50%) 2 Moderate + Poor (>0%) 2	
149 ↓ P Mild/mod/sev	**Overall change (Witkowski discretized %)**	Mid (10)	**Benzoyl peroxide (10%)** Excellent (>75%) 26 Good (>50%) 7 Moderate + Poor (>0%) 1	**NS**
149 ↓ P Mild/mod/sev	**Overall change (Witkowski discretized %)**	Mid (10)	**Benzoyl peroxide (5%)** Excellent (>75%) 28 Good (>50%) 9 Moderate + Poor (>0%) 4	**NS**

↑↓ refer to the presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. BETWEEN P-value indicates a comparison among arms of the study.

Trial	Discrete Outcome Name (Units) Comments re Between P-value	Follow up	Treatment	Between P-value
149 ↓ P Mild/mod/sev	**Overall change (Witkowski discretized %)**	Mid (10)	**Tretinoin** Excellent (>75%) 32 Good (>50%) 2 Moderate + Poor (>0%) 2	**0.01**
149 ↓ P Mild/mod/sev	**Side effects/Withdrawal**	Mid (10)	**Benzoyl peroxide (10%)** Allergy 1 Severe irritation reaction 12 Toxic reation 0	**0.05**
149 ↓ P Mild/mod/sev	**Side effects/Withdrawal**	Mid (10)	**Benzoyl peroxide (10%)** Allergy 1 Severe irritation reaction 12 Toxic reation 0	**0.05**
149 ↓ P Mild/mod/sev	**Side effects/Withdrawal**	Mid (10)	**Benzoyl peroxide (5%)** Allergy 2 Severe irritation reaction 2 Toxic reation 0	**0.05**
149 ↓ P Mild/mod/sev	**Side effects/Withdrawal**	Mid (10)	**Benzoyl peroxide (5%)** Allergy 2 Severe irritation reaction 2 Toxic reation 0	**0.05**
149 ↓ P Mild/mod/sev	**Side effects/Withdrawal**	Mid (10)	**Tretinoin** Allergy 0 Severe irritation reaction 11 Toxic reaction 0	**0.05**
149 ↓ P Mild/mod/sev	**Side effects/Withdrawal**	Mid (10)	**Tretinoin** Allergy 0 Severe irritation reaction 11 Toxic reaction 0	**0.05**
177 ↑ P	**Clinical assessed facial lesions**	Mid (12)	**Benzoyl peroxide** resolved 4 Much better 8 better 6 same 3 worse 2	
177 ↑ P	**Clinical assessed facial lesions**	Mid (12)	**Hydroxyquinoline + benzoyl peroxide** resolved 6 Much better 11 better 2 same 1	
177 ↑ P	**Clinical assessed facial lesions**	Mid (12)	**Vehicle** resolved 4 Much better 10 better 4 same 6 worse 1	

↑↓ refer to the presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. BETWEEN P-value indicates a comparison among arms of the study.

Trial	Discrete Outcome Name (Units) Comments re Between P-value	Follow up	Treatment	Between P-value
177 ↑ P	**Clinical assessment back lesions**	Mid (12)	**Benzoyl peroxide** resolved 2 Much better 2 better 5 same 4 worse	
177 ↑ P	**Clinical assessment back lesions**	Mid (12)	**Hydroxyquinoline + benzoyl peroxide** resolved 4 Much better 4 better 5 same 3	
177 ↑ P	**Clinical assessment back lesions**	Mid (12)	**Vehicle** resolved 3 Much better 3 better 4 same 4	
177 ↑ P	**Clinical assessment chest lesions**	Mid (12)	**Benzoyl peroxide** resolved 1 Much better 4 better 3 same 3	
177 ↑ P	**Clinical assessment chest lesions**	Mid (12)	**Hydroxyquinoline + benzoyl peroxide** resolved 2 Much better 3 better 3 same 2	
177 ↑ P	**Clinical assessment chest lesions**	Mid (12)	**Vehicle** resolved 3 Much better 2 better 3 same 3	
177 ↑ P	**Greasiness**		**Benzoyl peroxide** absent 7 Slight 13 moderate 4 marked	
177 ↑ P	**Greasiness**		**Hydroxyquinoline + benzoyl peroxide** absent 10 Slight 10 moderate 1 marked 1	
177 ↑ P	**Greasiness**		**Vehicle** absent 7 Slight 15 moderate 6 marked	

↑↓ refer to the presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. BETWEEN P-value indicates a comparison among arms of the study.

Trial	Discrete Outcome Name (Units) Comments re Between P-value	Follow up	Treatment	Between P-value
214 ↑	**Local side effects**	Mid (11)	**Benzoyl peroxide**	
P Mod			erythema 13 Peeling 19 dryness 7 burning 1 pruritis 2	**NS**
214 ↑	**Local side effects**	Mid (11)	**Clindamycin**	
P Mod			erythema 6 Peeling 7 dryness 5 burning 0 pruritis 1	**NS**
214 ↑	**Local side effects**	Mid (11)	**Clindamycin + benzoyl peroxide**	
P Mod			erythema 7 Peeling 21 dryness 8 burning 2 pruritis 2	**NS**
214 ↑	**Local side effects**	Mid (11)	**Vehicle**	
P Mod			erythema 6 Peeling 9 dryness 2 burning 1 pruritis 3	**NS**
214 ↑	**Overall change/physician**	Mid (11)	**Benzoyl peroxide**	
P Mod			excellent or good 38 Good, fair or worse 54	**0.01**
214 ↑	**Overall change/physician**	Mid (11)	**Clindamycin**	
P Mod			excellent or good 32 Good, fair or worse 57	**0.01**
214 ↑	**Overall change/physician**	Mid (11)	**Clindamycin + benzoyl peroxide**	
P Mod			excellent or good 63 Good, fair or worse 32	**0.01**
214 ↑	**Overall change/physician**	Mid (11)	**Vehicle**	
P Mod			excellent or good 6 Good, fair or worse 52	**NS**
233 ↑	**Side effects**	Mid (12)	**Vehicle**	
P Mod/sev			dry skin 0	
233 ↑	**Side effects**	Mid (12)	**Vitamin A palmitate**	
P Mod/sev			dry skin 0	
233 ↑	**Side effects**	Mid (12)	**Zinc sulfate**	
P Mod/sev			dry skin 4	
233 ↑	**Side effects**	Mid (12)	**Zinc sulfate + Vitamin A palmitate**	
P Mod/sev			dry skin 4	

↑↓ refer to the presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. BETWEEN P-value indicates a comparison among arms of the study.

Trial	Discrete Outcome Name (Units) Comments re Between P-value	Follow up	Treatment	Between P-value
238 ↓ P Mod/sev	**Overall change/physician**	Mid (8)	**Erythromycin** excellent (75% or greater) 1 Good (50-74%) 8 fair (25-49%) 7 poor (<24%) 4	
238 ↓ P Mod/sev	**Overall change/physician**	Mid (8)	**Erythromycin + tretinoin** excellent (75% or greater) 5 Good (50-74%) 10 fair (25-49%) 5 poor (<24%) 0	
238 ↓ P Mod/sev	**Overall change/physician**	Mid (8)	**Tretinoin** excellent (75% or greater) 5 Good (50-74%) 5 fair (25-49%) 6 poor (<24%) 4	
238 ↓ P Mod/sev	**Overall change/physician**	Mid (8)	**Vehicle** excellent (75% or greater) 0 Good (50-74%) 2 fair (25-49%) 6 poor (<24%) 12	
287 ↓ P	**Overall change/physician**	Long (16	**Hydrocortisone** improved 14 Unimproved 10	
287 ↓ P	**Overall change/physician**	Long (16	**Neomycin** improved 10 Unimproved 10	
287 ↓ P	**Overall change/physician**	Long (16	**Resorcinol** improved 17 Unimproved 7	
287 ↓ P	**Overall change/physician**	Long (16	**Resorcinol + neomycin + hydrocortisone F + sulfur** improved 21 Unimproved 11	
287 ↓ P	**Overall change/physician**	Long (16	**Sulfur** improved 11 Unimproved 12	
287 ↓ P	**Overall change/physician**	Long (16	**Vehicle** improved 14 Unimproved 12	
287 ↓ P	**Side effects**	Long (16	**Hydrocortisone** itching/erythema 2	
287 ↓ P	**Side effects**	Long (16	**Neomycin** itching/erythema 0	
287 ↓ P	**Side effects**	Long (16	**Resorcinol** itching/erythema 3	

↑↓ refer to the presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. BETWEEN P-value indicates a comparison among arms of the study.

Trial	Discrete Outcome Name (Units) Comments re Between P-value	Follow up	Treatment	Between P-value
287 ↓ P	**Side effects**	Long (16	**Resorcinol + neomycin + hydrocortisone F + sulfur** itching/erythema 2	
287 ↓ P	**Side effects**	Long (16	**Sulfur** itching/erythema 5	
287 ↓ P	**Side effects**	Long (16	**Vehicle** itching/erythema 2	
288 ↓ P	**Overall change/physician**	Long (16	**Hydrocortisone** improved 11 Unimproved 10	
288 ↓ P	**Overall change/physician**	Long (16	**Hydrocortisone + sulfur** improved 14 Unimproved 10	
288 ↓ P	**Overall change/physician**	Long (16	**Neomycin** improved 12 Unimproved 12	
288 ↓ P	**Overall change/physician**	Long (16	**Neomycin + resorcinol + hydrocortisone + sulfur** improved 12 Unimproved 11	
288 ↓ P	**Overall change/physician**	Long (16	**Neomycin + sulfur** improved 12 Unimproved 11	
288 ↓ P	**Overall change/physician**	Long (16	**Resorcinol** improved 12 Unimproved 13	
288 ↓ P	**Overall change/physician**	Long (16	**Sulfur** improved 12 Unimproved 11	
288 ↓ P	**Overall change/physician**	Long (16	**Vehicle** improved 12 Unimproved 13	
288 ↓ P	**Side effects**	Long (16	**Hydrocortisone** itching/eythema 0	
288 ↓ P	**Side effects**	Long (16	**Hydrocortisone + sulfur** itching/erythema 2	
288 ↓ P	**Side effects**	Long (16	**Neomycin** itching/erythema 3	
288 ↓ P	**Side effects**	Long (16	**Neomycin + resorcinol + hydrocortisone + sulfur** itching/erythema 1	
288 ↓ P	**Side effects**	Long (16	**Neomycin + sulfur** itching/erythema 2	
288 ↓ P	**Side effects**	Long (16	**Resorcinol** itching/erythema 3	

↑↓ refer to the presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. BETWEEN P-value indicates a comparison among arms of the study.

Trial	Discrete Outcome Name (Units) Comments re Between P-value	Follow up	Treatment	Between P-value
288 ↓ P	**Side effects**	Long (16	**Sulfur** itching/erythema 3	
288 ↓ P	**Side effects**	Long (16	**Vehicle** itching/erythema 0	
302 ↓ P s Mild	**Acne flare-up**		**Tretinoin (0.01%)** left study 1 No flare-up 19	
302 ↓ P s Mild	**Acne flare-up**		**Tretinoin combined** left study 3 No flare-up 17	
340 ↑ P Mod/sev	**Inter-treatment severity comparison**		**Erythromycin proprionate** more effective than placebo 5	
340 ↑ P Mod/sev	**Inter-treatment severity comparison**		**Erythromycin stearate** more effective than placebo 8	
340 ↑ P Mod/sev	**Inter-treatment severity comparison**		**Placebo** more effective than placebo 5	
340 ↑ P Mod/sev	**Inter-treatment severity comparison**		**Tetracycline phosphate** more effective than placebo 13	
340 ↑ P Mod/sev	**Inter-treatment severity comparison**		**Tetracycline-citric acid** more effective than placebo 13	
340 ↑ P Mod/sev	**Inter-treatment severity comparison**		**Tetracycline-novobiocin** more effective than placebo 3	
340 ↑ P Mod/sev	**Inter-treatment severity comparison**		**Triacetyl-oleandomycin** more effective than placebo 12	
349 ↓ P Mild/mod	**Improvement**	Mid (8)	**Ibuprofen + placebo** > 50% improvement 21 0-50% improvement 58 Worsening 21	
349 ↓ P Mild/mod	**Improvement**	Mid (8)	**Placebo** > 50% improvement 12 0-50% improvement 68 Worsening 20	
349 ↓ P Mild/mod	**Improvement**	Mid (8)	**Tetracycline + placebo** > 50% improvement 25 0-50% improvement 55 Worsening 20	
349 ↓ P Mild/mod	**Side effects overall**		**Ibuprofen + placebo** Withdrawal 1 Some symptoms 3 No symptoms 12	
349 ↓ P Mild/mod	**Side effects overall**		**Placebo** Withdrawal 1 Some symptoms 2 No symptoms 15	

↑↓ refer to the presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. BETWEEN P-value indicates a comparison among arms of the study.

Trial	Discrete Outcome Name (Units) Comments re Between P-value	Follow up	Treatment	Between P-value
349 ↓	**Side effects overall**		**Tetracycline + placebo**	
P Mild/mod			Withdrawal 1 Some symptoms 6 No symptoms 10	
349 ↓	**Side effects specific**		**Ibuprofen + placebo**	
P Mild/mod			Nausea 1 Vomiting 1 Diarrhea 1 Cramps/fullness 2 Other 1	
349 ↓	**Side effects specific**		**Placebo**	
P Mild/mod			Nausea 1 Vomiting 1 Diarrhea 1 Cramps/fullness 0 Other 0	
349 ↓	**Side effects specific**		**Tetracycline + placebo**	
P Mild/mod			Nausea 2 Vomiting 1 Diarrhea 0 Cramps/fullness 4 Other 1	
350 ↑	**Overall change/patient [acne conglobata]**	Long (24	**Grenz ray + hexachlorophene**	
P s Sev			improved 17 Worse 8	
350 ↑	**Overall change/patient [acne conglobata]**	Long (24	**Sham rays + hexachlorophene**	
P s Sev			improved 17 Worse 8	
350 ↑	**Overall change/patient [acne vulgaris]**	Long (24	**Grenz ray + hexachlorophene**	
P s Sev			yes 38 No 7	
350 ↑	**Overall change/patient [acne vulgaris]**	Long (24	**Grenz rays**	
P s Sev			yes 4 No 19	
350 ↑	**Overall change/patient [acne vulgaris]**	Long (24	**Sham rays + hexachlorophene**	
P s Sev			yes 38 No 7	
350 ↑	**Overall change/patient [acne vulgaris]**	Long (24	**Untreated**	
P s Sev			yes 4 No 19	
350 ↑	**Pigmentation**	Long (24	**Grenz ray + hexachlorophene**	
P s Sev			mentioned 55 Not mentioned 11	
350 ↑	**Pigmentation**	Long (24	**Sham rays + hexachlorophene**	
P s Sev			mentioned 55 Not mentioned 11	

↑↓ refer to the presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. BETWEEN P-value indicates a comparison among arms of the study.

Trial	Discrete Outcome Name (Units) Comments re Between P-value	Follow up	Treatment	Between P-value
350 ↑	**Severity change/patient-treated side [acne vulgaris]**	Long (24	**Grenz ray + hexachlorophene**	
P s Sev			treatment side better 19 Placebo side better 26 no change 0	
350 ↑	**Severity change/patient-treated side [acne vulgaris]**	Long (24	**Grenz rays**	
P s Sev			treatment side better 9 Placebo side better 11 no change 5	
350 ↑	**Severity change/patient-treated side [acne vulgaris]**	Long (24	**Sham rays + hexachlorophene**	
P s Sev			treatment side better 19 Placebo side better 26 no change	
350 ↑	**Severity change/patient-treated side [acne vulgaris]**	Long (24	**Untreated**	
P s Sev			treatment side better 9 Placebo side better 11 no change 5	

↑↓ refer to the presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., refer to our assessment of entry severity of study patients. "P" refers to parallel study, "S," to split face design. BETWEEN P-value indicates a comparison among arms of the study.